查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1968531

生物可吸收冠状动脉支架市场－全球产业规模、份额、趋势、机会、预测：按品牌、最终用户、地区和竞争对手划分，2021-2031年

Bioresorbable Coronary Stents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Brand, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球生物可吸收冠状动脉支架市场预计将从 2025 年的 5.5209 亿美元成长到 2031 年的 9.9147 亿美元，复合年增长率达到 10.25%。

这些装置可作为临时支架，疏通阻塞的动脉，恢復血流，然后逐渐溶解，从而有效避免植入永久性金属植入。市场成长的主要驱动因素是全球冠状动脉疾病发生率的上升，以及临床上对微创手术（支持血管自然修復）的偏好转变。此外，降低永久性金属支架相关的长期血栓形成风险的潜力，也促使介入心臟科医师采用这些装置，以期改善患者的治疗效果。

市场概览
预测期 2027-2031
市场规模：2025年 5.5209亿美元
市场规模：2031年 9.9147亿美元
复合年增长率：2026-2031年 10.25%
成长最快的细分市场 医院和诊所
最大的市场 北美洲

然而，阻碍市场快速成长的主要障碍在于，需要严格的长期临床数据来检验其安全性与标准药物释放型支架相当。这给获得监管部门核准带来了重大挑战。这种严格的审查迫使製造商投入大量资金进行漫长的临床试验，导致商业化进程的延迟。根据欧洲心臟学会的预测，到2024年，高所得成员国的经皮冠状动脉介入治疗率预计将达到每百万人2330例，这凸显了庞大的手术量，也显示儘管面临这些监管挑战，支架技术仍需要不断创新。

市场驱动因素

全球心血管疾病盛行率的不断上升是推动生物可吸收冠状动脉支架全球市场发展的主要因素，也使得日益增长的患者群体迫切需要先进的治疗方案。由于冠状动脉疾病仍然是重要的全球健康问题，因此，人们越来越需要能够恢復血管功能而无需留下永久性植入的治疗方法。根据美国心臟协会（AHA）于2025年1月发布的《2025年心血管和中风统计更新》，2021年全球约有1,941万人死于心血管疾病。生活方式相关的危险因子进一步加剧了这种死亡负担。世界心臟联盟于2025年5月发布的《2025年世界心臟报告》指出，高体重指数（BMI）每年导致190万人死于心血管疾病，凸显了冠状动脉技术进步的关键性。

生物可吸收材料技术的进步正透过解决传统支架的安全局限性，进一步推动市场发展。製造商正积极研发新一代支架，这些支架具有更细的支撑桿和更强的机械性能，可在血管恢復自然功能期间提供临时支撑。近期的一些成功案例也印证了这项进展。例如，Elixir Medical公司于2025年5月在EuroPCR会议上公布的「BIOADAPTOR随机对照试验」显示，DynamX冠状动脉生物适配器显着降低了3年目标病变失败率，从标准药物释放型支架的7.2%降至2.7%。这些数据对于恢復医生信心和促进自适应冠状动脉技术的广泛应用至关重要。

市场挑战

对长期临床数据的严格要求是全球生物可吸收冠状动脉支架市场成长的主要障碍。监管机构制定了高标准的证据要求，以确保这些临时支架的安全性与已上市的药物释放型支架相当，尤其是在溶解阶段血栓症等风险方面。这项要求迫使製造商在核准前进行长达数年的临床试验，显着增加了研发成本并延长了开发週期。因此，这种延长的週期造成了不确定性，阻碍了快速投资，并妨碍了这些创新器械迅速进入市场，挑战永久性金属植入的主导地位。

监管瓶颈直接限制了市场利用冠状动脉介入治疗高需求的能力。儘管心臟病负担沉重，但缓慢的产品核可限制了介入心臟科医生可选择的生物可吸收材料。根据欧洲心臟学会2024年报告，心血管疾病每年在成员国造成超过300万人死亡，清楚显示有大量患者需要有效的治疗。然而，由于製造商获取必要的安全数据需要耗费大量时间，市场渗透率不足，这实际上抑制了预期中从如此庞大的手术量中获得的收入成长。

市场趋势

从聚合物支架转向镁基金属支架，标誌着支架技术的重大革新，旨在克服早期聚左旋乳酸）支架的机械性能缺陷和吸收时间过长等问题。与聚合物不同，镁合金具有更优异的抗辐射强度，能够製造出更细的支架梁。这显着提高了支架的可靠性，同时减轻了血管壁的发炎负荷。这种材料的转变解决了安全隐患，确保支架在血管癒合后能够完全吸收，从而预防晚期血栓症。根据百奥特伦公司（Biotronic）2024年2月发布的关于FreeSolve支架获得CE认证的新闻稿，BIOMAG-I试验取得了卓越的成果，植入12个月后，99.3%的镁支架梁降解，证实了这些金属支架平台在快速恢復血管舒缩功能方面的有效性。

由于生物可吸收支架对尺寸误差的接受度低于永久性金属支架，因此引入先进的影像技术进行精准支架植入已成为优化其植入的关键标准。介入性心臟病专家正越来越多地使用光同调断层扫瞄（OCT）来确保支架充分扩张并与血管壁紧密贴合，从而最大限度地降低机械故障和急性血管回缩的风险。统计学研究已证实，整合这种影像导引技术能够提高临床安全性。如同欧洲心臟学会2024年9月发布的新闻稿所述，与标准血管造影术相比，在光同调断层扫瞄引导下接受治疗的患者发生心因性死亡、支架血栓症和再次血管重建的风险降低了38%。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：生物可吸收冠状动脉支架的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按品牌（Magmaris、Magnitude、Meres-100、Desolve、其他）
    • 依最终使用者（医院/诊所、门诊中心、其他）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美生物可吸收冠状动脉支架市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲生物可吸收冠状动脉支架市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区生物可吸收冠状动脉支架市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲生物可吸收冠状动脉支架市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲生物可吸收冠状动脉支架市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球生物可吸收冠状动脉支架市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • BIOTRONIK SE & Co. KG
  • Meril Life Sciences Pvt. Ltd
  • Elixir Medical Corporation.
  • Reva Medical, LLC
  • Terumo Corporation
  • Lepu Medical Technology（Beijing）Co.,Ltd
  • MicroPort Scientific Corporation
  • LifeTech Scientific Corporation
  • Boston Scientific Corporation
  • Medtronic plc

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 16356

The Global Bioresorbable Coronary Stents Market is projected to expand from USD 552.09 Million in 2025 to USD 991.47 Million by 2031, achieving a CAGR of 10.25%. These devices function as transient scaffolds that open obstructed arteries to restore blood flow before gradually dissolving, effectively eliminating the need for permanent metallic implants. The market's growth is primarily driven by the rising global incidence of coronary artery disease and a shift in clinical preference toward minimally invasive procedures that support natural vessel restoration. Furthermore, the potential to mitigate long-term thrombotic risks associated with permanent metal stents is encouraging adoption among interventional cardiologists aiming to enhance patient outcomes.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 552.09 Million
Market Size 2031USD 991.47 Million
CAGR 2026-203110.25%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

However, a major obstacle hindering rapid market growth is the stringent requirement for extensive long-term clinical data to verify safety profiles equivalent to standard drug-eluting stents, which creates a significant barrier to regulatory approval. This intense scrutiny compels manufacturers to invest in prolonged trials, thereby delaying commercialization. According to the European Society of Cardiology, high-income member nations reported a percutaneous coronary intervention rate of 2,330 per million people in 2024, highlighting the substantial procedural volume that demands continuous innovation in stent technology despite these regulatory challenges.

Market Driver

The escalating global prevalence of cardiovascular diseases serves as the primary engine for the Global Bioresorbable Coronary Stents Market, creating an urgent need for advanced therapeutic solutions for a growing patient population. As coronary artery disease remains a critical global health burden, there is an intensifying demand for interventions that can restore vessel physiology without leaving permanent implants. According to the American Heart Association's '2025 Heart Disease and Stroke Statistics Update' from January 2025, cardiovascular disease caused approximately 19.41 million global deaths in 2021. This mortality burden is exacerbated by lifestyle-related risk factors; the World Heart Federation's 'World Heart Report 2025' from May 2025 notes that high body mass index contributed to 1.9 million annual cardiovascular deaths, underscoring the critical need for evolving coronary technologies.

Technological advancements in bioresorbable material science are further propelling the market by resolving the safety limitations of earlier scaffold generations. Manufacturers are aggressively developing next-generation devices with thinner struts and enhanced mechanical properties to provide temporary support before allowing the vessel to resume natural function. This progress is validated by recent successes, such as Elixir Medical's May 2025 presentation at EuroPCR regarding the 'BIOADAPTOR Randomized Controlled Trial,' where the DynamX coronary bioadaptor showed a statistically significant reduction in target lesion failure rates to 2.7% at three years compared to 7.2% for standard drug-eluting stents. Such data is pivotal in restoring physician confidence and fostering the adoption of adaptive coronary technologies.

Market Challenge

The stringent requirement for rigorous long-term clinical data poses a significant barrier to the growth of the Global Bioresorbable Coronary Stents Market. Regulatory bodies enforce high evidentiary standards to ensure that these transient scaffolds maintain safety profiles comparable to established drug-eluting stents, particularly regarding risks such as thrombosis during the dissolution phase. This necessity forces manufacturers to commit to multi-year clinical trials before gaining approval, drastically inflating research costs and extending development timelines. Consequently, this prolonged cycle generates uncertainty and discourages rapid investment, preventing these innovative devices from quickly entering the market to challenge the dominance of permanent metallic implants.

This regulatory bottleneck directly limits the market's capacity to capitalize on the high demand for coronary interventions. Although the burden of heart disease is immense, the slow pace of product validation restricts the availability of bioresorbable options for interventional cardiologists. As reported by the European Society of Cardiology in 2024, cardiovascular disease causes over 3 million deaths annually across its member countries, highlighting the massive patient population requiring effective treatment. However, because manufacturers are impeded by the time-intensive process of generating required safety data, the market remains underpenetrated, and potential revenue growth from this high procedural volume is effectively stalled.

Market Trends

The transition from polymer-based to magnesium-based metallic scaffolds represents a critical evolution aimed at overcoming the mechanical inferiority and prolonged resorption times of early poly-L-lactic acid devices. Unlike polymers, magnesium alloys provide superior radial strength and allow for thinner struts, significantly improving deliverability while reducing the inflammatory burden on vessel walls. This shift in materials addresses safety concerns by ensuring the scaffold disappears once the vessel heals, thereby preventing late-stage thrombosis. According to Biotronik's February 2024 press release regarding CE-approval for the Freesolve scaffold, the BIOMAG-I trial demonstrated an exceptional 99.3% magnesium strut degradation 12 months after implantation, confirming the viability of these metallic platforms to rapidly restore natural vasomotion.

The implementation of advanced imaging for precision scaffold placement is emerging as a mandatory standard to optimize the implantation of bioresorbable devices, which are less forgiving of sizing errors than permanent metallic stents. Interventional cardiologists are increasingly utilizing optical coherence tomography to ensure proper scaffold expansion and apposition, minimizing the risk of mechanical failure or acute vessel recoil. This integration of imaging guidance is statistically proven to enhance clinical safety; as noted by the European Society of Cardiology in a September 2024 press release, patients treated with optical coherence tomography guidance experienced a 38% reduction in the combined risk of cardiac death, stent thrombosis, and revascularization compared to standard angiography.

Key Market Players

  • BIOTRONIK SE & Co. KG
  • Meril Life Sciences Pvt. Ltd
  • Elixir Medical Corporation.
  • Reva Medical, LLC
  • Terumo Corporation
  • Lepu Medical Technology (Beijing)Co.,Ltd
  • MicroPort Scientific Corporation
  • LifeTech Scientific Corporation
  • Boston Scientific Corporation
  • Medtronic plc

Report Scope

In this report, the Global Bioresorbable Coronary Stents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bioresorbable Coronary Stents Market, By Brand

  • Magmaris
  • Magnitude
  • MeRes-100
  • DESolve
  • Others

Bioresorbable Coronary Stents Market, By End User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Bioresorbable Coronary Stents Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bioresorbable Coronary Stents Market.

Available Customizations:

Global Bioresorbable Coronary Stents Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bioresorbable Coronary Stents Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Brand (Magmaris, Magnitude, MeRes-100, DESolve, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Bioresorbable Coronary Stents Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Brand
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bioresorbable Coronary Stents Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Brand
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Bioresorbable Coronary Stents Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Brand
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Bioresorbable Coronary Stents Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Brand
        • 6.3.3.2.2. By End User

7. Europe Bioresorbable Coronary Stents Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Brand
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bioresorbable Coronary Stents Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Brand
        • 7.3.1.2.2. By End User
    • 7.3.2. France Bioresorbable Coronary Stents Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Brand
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Bioresorbable Coronary Stents Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Brand
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Bioresorbable Coronary Stents Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Brand
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Bioresorbable Coronary Stents Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Brand
        • 7.3.5.2.2. By End User

8. Asia Pacific Bioresorbable Coronary Stents Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Brand
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Bioresorbable Coronary Stents Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Brand
        • 8.3.1.2.2. By End User
    • 8.3.2. India Bioresorbable Coronary Stents Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Brand
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Bioresorbable Coronary Stents Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Brand
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Bioresorbable Coronary Stents Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Brand
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Bioresorbable Coronary Stents Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Brand
        • 8.3.5.2.2. By End User

9. Middle East & Africa Bioresorbable Coronary Stents Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Brand
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Bioresorbable Coronary Stents Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Brand
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Bioresorbable Coronary Stents Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Brand
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Bioresorbable Coronary Stents Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Brand
        • 9.3.3.2.2. By End User

10. South America Bioresorbable Coronary Stents Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Brand
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Bioresorbable Coronary Stents Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Brand
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Bioresorbable Coronary Stents Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Brand
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Bioresorbable Coronary Stents Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Brand
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Bioresorbable Coronary Stents Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. BIOTRONIK SE & Co. KG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Meril Life Sciences Pvt. Ltd
  • 15.3. Elixir Medical Corporation.
  • 15.4. Reva Medical, LLC
  • 15.5. Terumo Corporation
  • 15.6. Lepu Medical Technology (Beijing)Co.,Ltd
  • 15.7. MicroPort Scientific Corporation
  • 15.8. LifeTech Scientific Corporation
  • 15.9. Boston Scientific Corporation
  • 15.10. Medtronic plc

16. Strategic Recommendations

17. About Us & Disclaimer